The Adolescent Indication for Buprenorphine: What It Is, What It Is Not, and Why It Matters

Adolescents with opioid use disorder remain the group least likely to receive medication treatment despite facing the most severe risks in the current fentanyl landscape. Recent discussions in the clinical literature highlight persistent gaps in treatment initiation and engagement among young people, yet many analyses rely on age classifications and regulatory interpretations that do not align with established pediatric drug development standards. In the United States, buprenorphine carries no formal approval for individuals younger than 18 years, even though international authorities recognize adolescent indications and multiple federal bodies support its use in youth. Long‑standing misconceptions about an age‑16 approval, combined with the common practice of merging adolescents and young adults into broad "youth" categories, contribute to structural and epistemic barriers that restrict access to evidence‑based care. Clarifying regulatory terminology and correcting these entrenched misunderstandings are essential steps toward improving buprenorphine access for adolescents in the fentanyl era.